PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32308538-10 2020 This can be explained by the increase in TAC concentration caused by CYP3A4 inhibition due to LMV and by the decrease in TAC concentration ascribed to the decrease in VRCZ concentration by CYP2C19 induction due to LMV. Tacrolimus 121-124 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 189-196 26239045-0 2016 Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. Tacrolimus 72-82 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 10-30 31096684-0 2019 Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation. Tacrolimus 90-100 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 27-34 31096684-2 2019 Here, we investigated the influence of genotypes of CYP3A5, CYP2C19, and POR on the concentration/dose (C/D) ratio of tacrolimus and episodes of acute graft-versus-host disease (GVHD) in Japanese recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Tacrolimus 118-128 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 60-67 31096684-8 2019 Our results suggest that CYP3A5, POR, and CYP2C19 polymorphisms are useful biomarkers for individualized dosage adjustment of tacrolimus in HSCT recipients. Tacrolimus 126-136 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 42-49 31244435-0 2019 Association of Genetic Variants in CYP3A4, CYP3A5, CYP2C8, and CYP2C19 with Tacrolimus Pharmacokinetics in Renal Transplant Recipients. Tacrolimus 76-86 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 63-70 27191765-1 2016 OBJECTIVE: Genetic polymorphisms of the P450 2C9 enzyme (CYP2C9), CYP2C19 and CYP3A5 gene are known to affect the metabolism of many drugs applied in liver transplant recipients, such as warfarin, voriconazole, and tacrolimus. Tacrolimus 215-225 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 66-73 26239045-1 2016 This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on tacrolimus pharmacokinetics when coadministered with voriconazole. Tacrolimus 80-90 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 36-62 26239045-6 2016 These results demonstrate that CYP2C19 genotypes influenced the exposure of tacrolimus when coadministered with voriconazole, although tacrolimus is mainly metabolized by CYP3A. Tacrolimus 76-86 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 31-38 21802143-0 2011 Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. Tacrolimus 33-43 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 134-141 21883747-1 2012 The shared metabolism of PPIs and tacrolimus through the CYP enzyme system has been associated with clinically significant drug interactions, especially in patients who are classified as CYP 2C19 PMs. Tacrolimus 34-44 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 187-195 21883747-3 2012 A drug interaction between tacrolimus and omeprazole, esomeprazole, but not lansoprazole, occurred in an 18-yr-old female kidney transplant recipient classified as a CYP 2C19 extensive (normal) metabolizer. Tacrolimus 27-37 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 166-174 23175667-3 2013 Omeprazole inhibits tacrolimus metabolism via CYP3A5 in patients carrying variant alleles of CYP2C19, increasing tacrolimus blood concentrations. Tacrolimus 20-30 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 93-100 23175667-3 2013 Omeprazole inhibits tacrolimus metabolism via CYP3A5 in patients carrying variant alleles of CYP2C19, increasing tacrolimus blood concentrations. Tacrolimus 113-123 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 93-100 23175667-7 2013 Genotyping of CYP3A5 and CYP2C19 in renal transplantation should be considered to be of interest when treating with tacrolimus and omeprazole, because CYP2C19*2/*2 variant indirectly elicits an increase of tacrolimus blood levels and, in our study population, the adverse effects described. Tacrolimus 116-126 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 25-32 23175667-7 2013 Genotyping of CYP3A5 and CYP2C19 in renal transplantation should be considered to be of interest when treating with tacrolimus and omeprazole, because CYP2C19*2/*2 variant indirectly elicits an increase of tacrolimus blood levels and, in our study population, the adverse effects described. Tacrolimus 116-126 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 151-158 23175667-7 2013 Genotyping of CYP3A5 and CYP2C19 in renal transplantation should be considered to be of interest when treating with tacrolimus and omeprazole, because CYP2C19*2/*2 variant indirectly elicits an increase of tacrolimus blood levels and, in our study population, the adverse effects described. Tacrolimus 206-216 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 25-32 23175667-7 2013 Genotyping of CYP3A5 and CYP2C19 in renal transplantation should be considered to be of interest when treating with tacrolimus and omeprazole, because CYP2C19*2/*2 variant indirectly elicits an increase of tacrolimus blood levels and, in our study population, the adverse effects described. Tacrolimus 206-216 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 151-158 21802143-1 2011 BACKGROUND: A drug interaction between oral tacrolimus (TAC) and lansoprazole (LAN) has been reported in patients with CYP2C19 hetero/homozygous mutations and the CYP3A5 *3/*3 genotype. Tacrolimus 44-54 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 119-126 21366650-3 2011 The objective of this study was to investigate how, 1 year after renal transplantation, CYP3A5 and CYP2C19 polymorphisms, biochemical parameters and coadministration with lansoprazole, influenced tacrolimus pharmacokinetics. Tacrolimus 196-206 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 99-106 23213600-7 2011 We suspect CYP2C19*2 (poor metaboliser) genotype status and concomitant treatment with lansoprazole, tacrolimus, and antiretroviral (ARV) medications resulted in hepatic decompensation. Tacrolimus 101-111 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 11-18 20596503-1 2010 BACKGROUND: As proton pump inhibitors share CYP3A4 enzyme with tacrolimus for their hepatic elimination, they potentially affect its pharmacokinetics, most prominently in patients with CYP2C19 or CYP3A5 gene mutations. Tacrolimus 63-73 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 185-192 19139162-0 2009 Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Tacrolimus 66-76 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 21-28 19139162-5 2009 Our findings suggest that intestinal and graft liver CYP2C19 plays a relatively greater role in the metabolism of omeprazole than it does for lansoprazole, so that the effects of CYP3A5 on the metabolism of tacrolimus might be masked by the interaction with omeprazole associated with the CYP2C19 genotype. Tacrolimus 207-217 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 53-60 19139162-5 2009 Our findings suggest that intestinal and graft liver CYP2C19 plays a relatively greater role in the metabolism of omeprazole than it does for lansoprazole, so that the effects of CYP3A5 on the metabolism of tacrolimus might be masked by the interaction with omeprazole associated with the CYP2C19 genotype. Tacrolimus 207-217 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 289-296 17377957-1 2007 The objective of this study was to evaluate whether genetic polymorphisms of CYP2C19, CYP3A5 and MDR1 significantly impact the interaction between tacrolimus and rabeprazole or lansoprazole. Tacrolimus 147-157 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 77-84 17377957-4 2007 The mean daily dose and the dose-adjusted area under the plasma concentration-time curves from 0 to 12 h (AUC(0-12)) of tacrolimus coadministered with rabeprazole or lansoprazole were the lowest and highest, respectively, in CYP2C19 poor metabolizers (PMs) having the CYP3A5*3/*3 genotype (0.084 and 0.112 mg/kg/day and 1.269 and 1.033 ng.h/ml/mg/kg, respectively). Tacrolimus 120-130 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 225-232 17377957-5 2007 On the other hand, the mean dose-adjusted AUC(0-12) of tacrolimus coadministered with rabeprazole or lansoprazole were the highest in CYP2C19 PMs having the MDR13435CC+CT genotype, but not significantly. Tacrolimus 55-65 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 134-141 17377957-6 2007 The present study indicates that there are significant interactions between tacrolimus and rabeprazole or lansoprazole in CYP2C19 PM renal transplant recipients bearing the CYP3A5*3/*3 genotypes. Tacrolimus 76-86 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 122-129 15010519-0 2004 Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Tacrolimus 13-23 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 74-81 15285851-1 2004 The aim of this study was to investigate the effects of the proton pump inhibitors (PPIs), lansoprazole and rabeprazole, on tacrolimus pharmacokinetics in healthy volunteers with mutations in the cytochrome P450 (CYP) 2C19 gene (CYP2C19). Tacrolimus 124-134 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 196-222 15285851-7 2004 Large individual variation was observed in the effects of lansoprazole on tacrolimus AUC0-8 owing to CYP2C19 genotype status. Tacrolimus 74-84 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 101-108 15285851-8 2004 The percent change for tacrolimus AUC0-8 in subjects with and without CYP2C19 mutant alleles was 81% and 29%, respectively. Tacrolimus 23-33 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 70-77 15285851-10 2004 These observations suggest that drug interaction between tacrolimus and lansoprazole occurs in subjects with higher lansoprazole blood concentrations corresponding to CYP2C19 genetic status. Tacrolimus 57-67 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 167-174 15010519-9 2004 Since tacrolimus is also metabolized by CYP3A4, the blood concentration of tacrolimus in this patient who had a CYP2C19 gene mutation may have been elevated by decreased hepatic elimination of lansoprazole. Tacrolimus 6-16 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 112-119 15010519-9 2004 Since tacrolimus is also metabolized by CYP3A4, the blood concentration of tacrolimus in this patient who had a CYP2C19 gene mutation may have been elevated by decreased hepatic elimination of lansoprazole. Tacrolimus 75-85 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 112-119 12431607-0 2002 Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. Tacrolimus 20-30 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 94-101 35508605-0 2022 The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients. Tacrolimus 38-48 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 18-25 35508605-8 2022 Besides, the fold changes of tacrolimus dose were associated with CYP2C19 genotype, which was found to be significantly lower in CYP2C19 extensive metabolizers than that in CYP2C19 intermediate metabolizers or poor metabolizers (4.06+-1.85 vs 5.49+-2.47, p=0.0031). Tacrolimus 29-39 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 66-73 35508605-8 2022 Besides, the fold changes of tacrolimus dose were associated with CYP2C19 genotype, which was found to be significantly lower in CYP2C19 extensive metabolizers than that in CYP2C19 intermediate metabolizers or poor metabolizers (4.06+-1.85 vs 5.49+-2.47, p=0.0031). Tacrolimus 29-39 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 129-136 35508605-8 2022 Besides, the fold changes of tacrolimus dose were associated with CYP2C19 genotype, which was found to be significantly lower in CYP2C19 extensive metabolizers than that in CYP2C19 intermediate metabolizers or poor metabolizers (4.06+-1.85 vs 5.49+-2.47, p=0.0031). Tacrolimus 29-39 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 173-180 35508605-10 2022 Moreover, CYP2C19 genotype and hematocrit acted as independent predicting factors for tacrolimus dose modification after voriconazole co-therapy. Tacrolimus 86-96 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 10-17 35508605-12 2022 CYP2C19 genotype and hematocrit should be considered in tailoring tacrolimus dose. Tacrolimus 66-76 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 0-7